Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: A morphometric study

Leukemia

Volumn 17, Issue 1, 2003, Pages 89-97

  Korkolopoulou, P ^a   Viniou, N ^a   Kavantzas, N ^a   Patsouris, E ^a   Thymara, I ^a   Pavlopoulos, P M ^a   Terpos, E ^a   Stamatopoulos, K ^a   Plata, E ^a   Anargyrou, K ^a   Androulaki, A ^a   Davaris, P ^a   Yataganas, X ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiogenesis; Chronic myeloid leukemia; Microvessel morphometry

Indexed keywords

ALPHA2B INTERFERON; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROVASCULARIZATION; MICROVASCULATURE; MORPHOMETRICS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; THROMBOCYTE COUNT;

EID: 0037269498     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402769     Document Type: Article

References (48)

1. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
2. Schnitt SJ. The real value of angiogenesis research in breast cancer. Adv Anat Path 1997; 4: 23-27.
3. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 1988; 133: 419-423.
4. Korkolopoulou P, Konstantinidou AE, Kavantzas N, Patsouris E, Pavlopoulos PM, Christodoulou P, Thomas-Tsagli E, Davaris P. Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virch Arch 2001; 438: 603-611.
5. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73: 678-687.
6. Pavlopoulos PM, Konstantinidou AE, Agapitos E, Kavantzas N, Nikolopoulou P, Davaris P. A morphometric study of neovascularization in colorectal carcinoma. Cancer 1998; 83: 2067-2075.
7. Yamazaki K, Abe S, Tagekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K, Kawakami Y. Tumor angiogenesis in human lung adenocarcinoma. Cancer 1994; 74: 2245-2250.
8. Bruyn PPH, Breen PC, Thomas TB. The microcirculation of the bone marrow. Anat Rec 1970; 168: 55-68.
9. Mangi MH. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000; 111: 43-51.
10. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-732.
11. Yamaguchi H, Ishii E, Saito S, Tashiro K, Fujita I, Yoshidani S, Ohtubo M, Akazawa K, Miyazaki S. Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Br J Haematol 1996; 94: 606-611.
12. Fiedler W, Graeven U, Ergn S, Verago S, Kilie N, Stockschlader M, Hossfeld DK. Vascular endothelial growth factor, a possible paracrine growth factor, in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
13. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
14. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and structural study. Eur J Haematol 1996; 56: 45-53.
15. Perez-Atayde AR, Sallan SE, Tedrow V, Connors S, Alfred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
16. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estror Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
17. Padrö T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
18. de Bont ESJM, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
19. Aguayo A, Estey E, Kantarjian H, Manshouri T, Gidel C, Keating M, Giles F, Estror Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
20. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Keller C, Kantarjian H, Albitar M. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 768-770.
21. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and βFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712-3718.
22. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol 2000; 157: 15-19.
23. Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer 2002; 94: 1517-1521.
24. Gunsilius E, Duba HC, Petzer AL, Kahler CM, Grunewald K, Stockhammer G, Gabl C, Dirnhofer S, Clausen J, Gastl G. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000; 355: 1688-1691.
25. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermenlink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-87.
26. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Johanna C, Nelemans K, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858.
27. Sokal J, Cox E, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C, and the Italian Cooperative CML Study Group. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 1984; 63: 1352-1357.
28. Mesa RA, Hanson CA, Rajkumar V, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374-3380.
29. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzela F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398-1401.
30. Shi SR, Key ME, Kalra K. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.
31. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
32. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzela F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32: 2474-2484.
33. Weidner N, Folkman J, Pozza F, Bevilacqua P. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887.
34. Fox E, Ulrich C. Sigma Scan Image Measurement Software, User's Electronic Manual, 1995. Sigma Scan, Jandel Scientific: Erkrath, Germany.
35. Branemark P-I. Bone marrow microvascular structure and function. Adv Microcirc 1968; 1: 1-65.
36. Korkolopoulou P, Apostolidou E, Pavlopoulos PM, Kavantzas N, Vyniou N, Thymara I, Terpos E, Patsouris E, Yataganas X, Davaris P. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 2001; 15: 1369-1376.
37. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94: 8761-8766.
38. Patan S, Munn LL, Jain PK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 1996; 51: 260-272.
39. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, Garcia-Arroyo A, Garcia-Sanchez A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-241.
40. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. VEGF is an autocrine promoter of abnormal localized immature myeloid precursors and leukemic progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
41. Green AR. Hemangioblast origin of chronic myeloid leukaemia? Lancet 2000; 355: 1659-1660.
42. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy M, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116.
43. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Scmenza GL, Simons JW. Overexression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
44. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MR, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-1276.
45. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78-83.
46. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-965.
47. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349: 13-15.
48. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.